Alpine Immune Sciences (NASDAQ:ALPN) Sees Strong Trading Volume

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) saw an uptick in trading volume on Friday . 1,679,280 shares were traded during trading, a decline of 7% from the previous session’s volume of 1,802,868 shares.The stock last traded at $64.50 and had previously closed at $64.40.

Analysts Set New Price Targets

A number of research firms recently weighed in on ALPN. Wedbush lowered shares of Alpine Immune Sciences from an “outperform” rating to a “neutral” rating in a research note on Thursday. Leerink Partnrs lowered shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a research note on Thursday. Wolfe Research restated a “peer perform” rating on shares of Alpine Immune Sciences in a research note on Thursday. Oppenheimer restated an “outperform” rating and set a $44.00 target price (up from $33.00) on shares of Alpine Immune Sciences in a research note on Tuesday, March 19th. Finally, Guggenheim started coverage on Alpine Immune Sciences in a report on Tuesday, April 9th. They issued a “buy” rating and a $55.00 price target for the company. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $50.33.

Alpine Immune Sciences Stock Down 0.0 %

The firm has a market capitalization of $4.22 billion, a price-to-earnings ratio of -100.58 and a beta of 1.14. The company has a fifty day moving average price of $36.42 and a two-hundred day moving average price of $23.04.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings data on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.47. The business had revenue of $30.85 million during the quarter, compared to the consensus estimate of $6.90 million. Alpine Immune Sciences had a negative return on equity of 15.54% and a negative net margin of 54.66%. On average, equities analysts anticipate that Alpine Immune Sciences, Inc. will post -1.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alpine Immune Sciences

Several large investors have recently modified their holdings of the company. Royal Bank of Canada lifted its holdings in shares of Alpine Immune Sciences by 99.1% during the second quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 1,315 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Alpine Immune Sciences by 745.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,312 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in shares of Alpine Immune Sciences during the third quarter worth $35,000. Barclays PLC lifted its holdings in shares of Alpine Immune Sciences by 818.4% during the fourth quarter. Barclays PLC now owns 6,080 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 5,418 shares during the period. Finally, BNP Paribas Arbitrage SNC lifted its holdings in shares of Alpine Immune Sciences by 88.7% during the third quarter. BNP Paribas Arbitrage SNC now owns 6,572 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 3,090 shares during the period. 75.17% of the stock is owned by institutional investors and hedge funds.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.